Bayesian Capital Management, LP Vericel Corp Transaction History

Bayesian Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$41.71 - $52.9 $248,716 - $315,442	5,963 New	5,963 $273,000
Q2 2019 Aug 13, 2019	SELL	$15.01 - $18.89 $340,727 - $428,803	-22,700 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$16.23 - $20.29 $387,897 - $484,931	-23,900 Reduced 51.29%	22,700 $397,000
Q4 2018 Feb 13, 2019	BUY	$10.77 - $18.44 $501,882 - $859,304	46,600 New	46,600 $811,000
Q2 2018 Aug 14, 2018	SELL	$9.6 - $14.6 $230,400 - $350,400	-24,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$5.7 - $12.3 $136,800 - $295,200	24,000 New	24,000 $239,000

276

48.8M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.48B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.